Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy
The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Abstract
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with an unknown etiology and currently few effective therapies. Immune system alterations have being demonstrated in ASD, both in humans and via animal models; immune imbalance thus arises as a possible pathway for drug intervention. In this review, the studies were classified into 2 major groups: (1) clinical research whose authors classify therapies with primary anti-inflammatory and immunomodulatory actions, making use of: sulforaphane, celecoxib, lenalidomide, pentoxifylline, spironolactone, flavonoid luteolin, corticosteroids, oral immunoglobulin, intravenous immunoglobulin, cell therapy, dialyzable lymphocyte extracts, minocycline, and pioglitazone; and (2) other ASD therapies already used or currently under study whose initial characteristics were neither anti-inflammatory nor immunomodulatory initially, but displayed a capacity for immunomodulation throughout the treatment: risperidone, vitamin D, omega-3, Ginkgo biloba, L-carnosine, N-acetylcysteine, and microbiome restoration. These studies used various data acquisition methodologies. Questions arose such the need for randomized and placebo-controlled studies with greater numbers of participants as well as the use of biomarkers to refine the treatment of autistic subjects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, studies in human and animal models indicate immunological dysfunction in ASD (61), while recent research highlights the co-ocurrence of mast cell dysregulation in EDS (62, 63) suggesting problems in the immune system.”
From Autism, joint hypermobility-related disorders and pain (2018) · cites this paper as [61]
Citations
Cites
1 retracted
Saad, K., Abdel‐Rahman, A. A., Elserogy, Y. M., Al‐Atram, A. A., El‐Houfey, A. A., Othman, H. A. K., Bjørklund, G., Jia, F., Urbina, M. A., Abo‐Elela, M. G. M., et al. (2018) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12652 · Cited by 99
RetractedMiddleton, E., Kandaswami, C., & Theoharides, T. C. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01472-8 · Cited by 4,882
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Kang, D.-W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., McDonough-Means, S., et al. (2017) · Microbiome · doi:10.1186/s40168-016-0225-7 · Cited by 1,391
Costs of Autism Spectrum Disorders in the United Kingdom and the United States
Buescher, A. V. S., Cidav, Z., Knapp, M., & Mandell, D. S. (2014) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2014.210 · Cited by 1,296
The epidemiology and global burden of autism spectrum disorders
Baxter, A. J., Brugha, T. S., Erskine, H. E., Scheurer, R. W., Vos, T., & Scott, J. G. (2015) · Psychological Medicine · doi:10.1017/s003329171400172x · Cited by 1,224
Distribution and biological activities of the flavonoid luteolin
Lopez-Lazaro, M. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709787001712 · Cited by 1,106
Ashwood, P., Krakowiak, P., Hertz-Picciotto, I., Hansen, R., Pessah, I., & Van de Water, J. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.08.003 · Cited by 940
Molecular basis for chemoprevention by sulforaphane: a comprehensive review
Juge, N., Mithen, R. F., & Traka, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6484-5 · Cited by 693
Short-Term Benefit From Oral Vancomycin Treatment of Regressive-Onset Autism
Sandler, R. H., Finegold, S. M., Bolte, E. R., Buchanan, C. P., Maxwell, A. P., Väisänen, M.-L., Nelson, M. N., & Wexler, H. M. (2000) · Journal of Child Neurology · doi:10.1177/088307380001500701 · Cited by 614
Cited by
Brain-body interactions underlying the association of loneliness with mental and physical health
Quadt, L., Esposito, G., Critchley, H. D., & Garfinkel, S. N. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.06.015 · Cited by 137
Autism spectrum disorder: pathogenesis, biomarker, and intervention therapy
Zhuang, H., Liang, Z., Ma, G., Qureshi, A., Ran, X., Feng, C., Liu, X., Yan, X., & Shen, L. (2024) · MedComm · doi:10.1002/mco2.497 · Cited by 136
The role of natural products in revealing NRF2 function
Zhang, D. D., & Chapman, E. (2020) · Natural Product Reports · doi:10.1039/c9np00061e · Cited by 124
Trzmiel, T., Purandare, B., Michalak, M., Zasadzka, E., & Pawlaczyk, M. (2019) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2018.11.004 · Cited by 96
Chang, J. P., & Su, K. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.4.469 · Cited by 82
Metadata
- Authors
- Marchezan, J., Winkler dos Santos, E. G. A., Deckmann, I., & Riesgo, R. D. S.
- Affiliations
- Universidade Federal do Rio Grande do Sul (BR)
- Venue
- Neuroimmunomodulation
- Publisher
- S. Karger AG
- Published
- 2018
- Volume
- 25
- Issue
- 5-6
- Pages
- 300-319
- ISSN
- 1021-7401 (ISSN-L)
- 1423-0216
- OpenAlex
- W2892087768
- Cited by
- 70
- References
- 236
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 9 · 2023: 10 · 2022: 10 · 2021: 14 · 2020: 13 · 2019: 4 · 2018: 3
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- NeuroImmunoModulation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Child Nutrition and Feeding Issues
- Keywords
- autism spectrum disorder, immune dysfunction, immunomodulatory therapy, anti-inflammatory therapy, sulforaphane, celecoxib, lenalidomide, pentoxifylline, spironolactone, luteolin, corticosteroids, intravenous immunoglobulin, oral immunoglobulin, cell therapy, minocycline, pioglitazone, risperidone, vitamin D, omega-3 fatty acids, Ginkgo biloba, L-carnosine, N-acetylcysteine, microbiota restoration, biomarkers
- MeSH terms
- Autism Spectrum Disorder, Animals, Humans, Immunotherapy, Neuroimmunomodulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy. https://app.cochat.ai/papers/10.1159/000492225
- The paper
- Marchezan, J., Winkler dos Santos, E. G. A., Deckmann, I., & Riesgo, R. D. S. (2018). Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy. Neuroimmunomodulation. https://doi.org/10.1159/000492225
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.